Mark Goldsmith
February 13, 2020 06:52 AM ESTUpdated February 14, 01:06 PM
Financing

The RAS rush: Rev­o­lu­tion Med­i­cines bags re­mark­able $238M IPO raise, more than dou­bling orig­i­nal goal

Amber Tong

Rev­o­lu­tion Med­i­cines made it.

Less than a month af­ter pen­cilling in $100 mil­lion for its IPO — di­vulging some de­tails about its for­ay in­to the red …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Aca­dia snaps up an es­sen­tial tremor drug af­ter field­'s sum­mer set­backs

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

A service from the Financial Times